None listed
Conditions
Brief summary
The aim of this comparative prospective study was to compare laboratory and clinical outcomes of IMSI and conventional ICSI in couples with severe OAT.
Interventions
All the cases with severe oligoathenospermia (OAT) from 2012 to 2013 were counseled about the efficacy of the intracystoplasmic morphologicaly selected sperm injection (IMSI ) technique and its possible role for increasing the pregnancy rate, those accepted and consented on the new technique were enrolled in the study for IMSI group. For IMSI, spermatozoa were selected at 6600× magnification using an inverted microscope equipped with Nomarski (differential interference contrast) optics. it may be administered on multiple occasions within a given time period. IMSI is an advanced and sophisticated method of ICSI, where prior to sperm injection, the morphology of the sperm is evaluated under high magnification. In addition, the IMSI procedure involves a few minor modifications in sperm preparation which are not carried out during the conventional ICSI procedure, such as the use of MSOME criteria, the requirement for a glass-bottomed dish for selection, prolonged sperm manipulation following separation from the seminal fluid, and sperm storage prior to microinjection. The maximal number of times that this procedure may be undertaken in each couple is 3 times, and the overall duration of the intervention period is once every 2 months.
Sponsors
Study design
Eligibility
Inclusion criteria
very poor semen quality characterized by severe oligo-astheno-teratozoospermia (sperm concentration less than 5 million per ml, less than 50% motile sperms according to WHO criteria and less than 14% morphologically normal spermatozoa according to the Strict Kruger Criteria), a normal karyotype in both partners .
Exclusion criteria
Uterine defects, hydrosalpinx, endometriosis, polycystic ovaries, evidence of low ovarian response in previous treatment cycles (less than four oocytes retrieved), infections, endocrinal problems, coagulation defects or thrombophilia and autoimmune defects (including antiphospholipid antibodies) were all excluded.